CPTx, an innovative biotech startup committed to pioneering next-generation preventative and therapeutic solutions, announced it has raised $29 million from a diverse group of public and private investors. This funding round was led by Blueyard Capital and SPRIND, with participation from Marius Nacht Group, Andrej Henkler – Leblon Capital, Bayern Kapital, and several industry veterans, including Stefan Oschmann, former CEO of Merck KGaA.
CPTx builds on 15 years of transformative research in programmable DNA nanofabrication conducted at the Technical University of Munich by CPTx’s Founder and CEO Prof. Hendrik Dietz. This research advances antiviral therapy and also paves the way for broader biopharma applications beyond infectious diseases, signaling a new era of versatile therapeutic solutions.
CPTx specializes in large-scale DNA single strand synthesis, DNA nanostructure creation for multivalent drug display, and advanced pharmacokinetics (PK) and conjugate engineering. And these capabilities underpin CPTx’s rapidly evolving pipeline, which includes a pan-influenza antiviral and two promising partnership assets.
CPTx plans on using the funds to further develop its antiviral platform, advance its pipeline candidates, and expand its team. And the company’s vision is to lead the field in creating therapies that are not only effective but also adaptable to a wide range of viral threats, offering both preventative and therapeutic solutions.
As CPTx continues to grow, the company remains committed to its goal of transforming the antiviral landscape through innovation and collaboration. And with a strong pipeline, exceptional leadership and the backing of leading investors, CPTx is poised to make a significant impact in the fight against viral diseases.
KEY QUOTES:
“We are excited to have the support of such distinguished investors as we push the boundaries of antiviral therapy and expand the horizons of therapeutic innovation. This funding will help us accelerate the development of our platform and advance our pipeline products, enabling us to address a broad spectrum of health challenges.”
-Hendrik Dietz, CEO and Founder of CPTx
“CPTx is leading a transformative shift in therapeutic development. Our innovative approach not only targets viral infections but also has the potential to revolutionize how we approach a wide range of health threats. I am proud to support this pioneering team.”
-Stefan Oschmann, Chairman of the Board at CPTx
“Our platform’s ability to scale DNA manufacturing and engineer advanced nanoagents for multivalent drug display is unparalleled. This positions CPTx to deliver groundbreaking solutions that are both effective and scalable.”
-Grant Boldt, COO of CPTx and former head of biologics at Lonza
“CPTx is tackling one of the most critical challenges in healthcare with a highly innovative approach. We are thrilled to support their mission and look forward to their progress in developing a versatile platform capable of addressing a wide range of health issues. Their unique blend of scientific rigor and entrepreneurial drive makes CPTx a standout in the biotech space.”
-Jason Whitmire, Partner at Blueyard Capital
“CPTx has a strong management team and an innovative technology to target the huge unmet need in preventing and treating viral diseases.”
-Gur Roshwalb, representing the Nacht investment group and current CEO of 1ETherapeutics
“At SPRIND, we support innovations that can significantly impact society. CPTx’s work exemplifies this vision with their groundbreaking approach to antivirals and broader therapeutics. We believe their platform has the potential to redefine the field.”
-Rafael Laguna, Director of Germany’s Federal Agency for Disruptive Innovation SPRIND
